Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

The role of mitochondria in the pathogenesis of type 2 diabetes.

Patti ME, Corvera S.

Endocr Rev. 2010 Jun;31(3):364-95. doi: 10.1210/er.2009-0027. Epub 2010 Feb 15. Review.

2.

CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice.

Jourdan T, Djaouti L, Demizieux L, Gresti J, Vergès B, Degrace P.

Diabetes. 2010 Apr;59(4):926-34. doi: 10.2337/db09-1482. Epub 2010 Jan 28.

3.

Reduced cannabinoid receptor 1 protein in subcutaneous adipose tissue of obese.

Bennetzen MF, Nielsen TS, Paulsen SK, Bendix J, Fisker S, Jessen N, Lund S, Richelsen B, Pedersen SB.

Eur J Clin Invest. 2010 Feb;40(2):121-6. doi: 10.1111/j.1365-2362.2009.02231.x. Epub 2009 Dec 21.

PMID:
20039929
4.

The role of ATF-2 family transcription factors in adipocyte differentiation: antiobesity effects of p38 inhibitors.

Maekawa T, Jin W, Ishii S.

Mol Cell Biol. 2010 Feb;30(3):613-25. doi: 10.1128/MCB.00685-09. Epub 2009 Nov 30.

5.

CB1 antagonists for obesity--what lessons have we learned from rimonabant?

Di Marzo V, Després JP.

Nat Rev Endocrinol. 2009 Nov;5(11):633-8. doi: 10.1038/nrendo.2009.197.

PMID:
19844251
6.

Signal transduction of the CB1 cannabinoid receptor.

Turu G, Hunyady L.

J Mol Endocrinol. 2010 Feb;44(2):75-85. doi: 10.1677/JME-08-0190. Epub 2009 Jul 20. Review.

7.

The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.

Di Marzo V.

Pharmacol Res. 2009 Aug;60(2):77-84. doi: 10.1016/j.phrs.2009.02.010. Epub 2009 Mar 4. Review.

PMID:
19559360
8.

Anandamide increases the differentiation of rat adipocytes and causes PPARgamma and CB1 receptor upregulation.

Karaliota S, Siafaka-Kapadai A, Gontinou C, Psarra K, Mavri-Vavayanni M.

Obesity (Silver Spring). 2009 Oct;17(10):1830-8. doi: 10.1038/oby.2009.177. Epub 2009 Jun 18.

9.

AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity.

Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P, Auwerx J.

Nature. 2009 Apr 23;458(7241):1056-60. doi: 10.1038/nature07813.

10.

Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors.

Di Marzo V, Côté M, Matias I, Lemieux I, Arsenault BJ, Cartier A, Piscitelli F, Petrosino S, Alméras N, Després JP.

Diabetologia. 2009 Feb;52(2):213-7. doi: 10.1007/s00125-008-1178-6.

PMID:
18972095
11.

The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase.

Esposito I, Proto MC, Gazzerro P, Laezza C, Miele C, Alberobello AT, D'Esposito V, Beguinot F, Formisano P, Bifulco M.

Mol Pharmacol. 2008 Dec;74(6):1678-86. doi: 10.1124/mol.108.049205. Epub 2008 Sep 18.

12.

The endocannabinoid system in obesity and type 2 diabetes.

Di Marzo V.

Diabetologia. 2008 Aug;51(8):1356-67. doi: 10.1007/s00125-008-1048-2. Epub 2008 Jun 18. Review.

PMID:
18563385
13.

Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes.

Tedesco L, Valerio A, Cervino C, Cardile A, Pagano C, Vettor R, Pasquali R, Carruba MO, Marsicano G, Lutz B, Pagotto U, Nisoli E.

Diabetes. 2008 Aug;57(8):2028-36. doi: 10.2337/db07-1623. Epub 2008 May 13.

14.

Acquired obesity and poor physical fitness impair expression of genes of mitochondrial oxidative phosphorylation in monozygotic twins discordant for obesity.

Mustelin L, Pietiläinen KH, Rissanen A, Sovijärvi AR, Piirilä P, Naukkarinen J, Peltonen L, Kaprio J, Yki-Järvinen H.

Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E148-54. doi: 10.1152/ajpendo.00580.2007. Epub 2008 May 6.

15.

Transcriptional paradigms in mammalian mitochondrial biogenesis and function.

Scarpulla RC.

Physiol Rev. 2008 Apr;88(2):611-38. doi: 10.1152/physrev.00025.2007. Review.

16.

Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets.

Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA, Di Marzo V.

Mol Cell Endocrinol. 2008 Apr 16;286(1-2 Suppl 1):S66-78. doi: 10.1016/j.mce.2008.01.026. Epub 2008 Feb 9.

PMID:
18343566
17.

Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet.

Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, Izzo AA, Di Marzo V.

Obesity (Silver Spring). 2008 Mar;16(3):553-65. doi: 10.1038/oby.2007.106. Epub 2008 Jan 17.

18.

Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death.

Athanasiou A, Clarke AB, Turner AE, Kumaran NM, Vakilpour S, Smith PA, Bagiokou D, Bradshaw TD, Westwell AD, Fang L, Lobo DN, Constantinescu CS, Calabrese V, Loesch A, Alexander SP, Clothier RH, Kendall DA, Bates TE.

Biochem Biophys Res Commun. 2007 Dec 7;364(1):131-7. Epub 2007 Oct 2.

PMID:
17931597
19.

The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms.

Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G, Bianchi K, Rizzuto R, Bernante P, Federspil G, Vettor R.

J Clin Endocrinol Metab. 2007 Dec;92(12):4810-9. Epub 2007 Sep 4.

PMID:
17785353
20.

Peroxisome proliferator activator receptor gamma coactivator-1 expression is reduced in obesity: potential pathogenic role of saturated fatty acids and p38 mitogen-activated protein kinase activation.

Crunkhorn S, Dearie F, Mantzoros C, Gami H, da Silva WS, Espinoza D, Faucette R, Barry K, Bianco AC, Patti ME.

J Biol Chem. 2007 May 25;282(21):15439-50. Epub 2007 Apr 6.

Items per page

Supplemental Content

Write to the Help Desk